Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Other Non-Current Assets (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Other Non-Current Assets for 13 consecutive years, with $16.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Assets fell 54.67% year-over-year to $16.5 million, compared with a TTM value of $16.5 million through Sep 2025, down 54.67%, and an annual FY2024 reading of $5.2 million, down 87.19% over the prior year.
  • Other Non-Current Assets was $16.5 million for Q3 2025 at Tandem Diabetes Care, down from $17.3 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $40.3 million in Q4 2023 and bottomed at $5.2 million in Q4 2024.
  • Average Other Non-Current Assets over 5 years is $20.4 million, with a median of $16.6 million recorded in 2021.
  • The sharpest move saw Other Non-Current Assets surged 388.37% in 2021, then crashed 87.19% in 2024.
  • Year by year, Other Non-Current Assets stood at $15.7 million in 2021, then surged by 50.25% to $23.6 million in 2022, then soared by 70.69% to $40.3 million in 2023, then plummeted by 87.19% to $5.2 million in 2024, then skyrocketed by 219.8% to $16.5 million in 2025.
  • Business Quant data shows Other Non-Current Assets for TNDM at $16.5 million in Q3 2025, $17.3 million in Q2 2025, and $7.5 million in Q1 2025.